Recent News

• 08.05.2026 - Editas Medicine Announces Second Quarter 2026 Results and Business Updates
• 08.04.2026 - Editas Medicine Strengthens Board of Directors with Appointment of Patrick T. Ellinor, M.D., Ph.D.
• 08.04.2026 - Editas Medicine Strengthens Board of Directors with Appointment of Patrick T. Ellinor, M.D., Ph.D.
• 05.28.2026 - Editas Medicine Announces Updated Presentation Time for Upcoming Investor Conference
• 05.26.2026 - Editas Medicine Announces Pricing of Up to $319.4 Million Public Offering
• 05.26.2026 - Editas Medicine Announces Proposed Public Offering
• 05.26.2026 - Editas Medicine Presents EDIT-401 Preclinical Data Demonstrating Robust Reductions in LDL-C, Lp(a), and ApoB in Non-Human Primates at the 94th European Atherosclerosis Society Congress
• 05.14.2026 - Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting
• 04.27.2026 - Editas Medicine to Present New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at Upcoming Scientific Conferences
• 11.03.2025 - Editas Medicine Announces EDIT-401 Poster Presentation at the American Heart Association (AHA) Scientific Sessions 2025

Recent Filings

• 08.07.2026 - 4 Statement of changes in beneficial ownership of securities
• 08.07.2026 - 3 Initial statement of beneficial ownership of securities
• 08.05.2026 - 8-K Current report
• 08.05.2026 - 4 Statement of changes in beneficial ownership of securities
• 08.05.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 07.29.2026 - 4 Statement of changes in beneficial ownership of securities
• 07.29.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 07.21.2026 - 144 Report of proposed sale of securities
• 06.22.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.22.2026 - 4 Statement of changes in beneficial ownership of securities